Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


10.02.2025

1 Am J Clin Oncol
1 Ann Oncol
4 Ann Surg Oncol
5 Anticancer Res
3 BMC Cancer
1 Br J Cancer
3 Breast Cancer
1 Breast Cancer (Dove Med Press)
4 Breast Cancer Res
20 Breast Cancer Res Treat
1 Cancer
1 Cancer Cell
1 Cancer Epidemiol Biomarkers Prev
2 Cancer Lett
3 Cancer Res
1 Cell
4 Clin Breast Cancer
4 Clin Cancer Res
3 Eur Radiol
2 Gene
3 Histopathology
4 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
2 Lancet
1 Nature
2 NPJ Breast Cancer
3 Oncogene
2 Oncology
2 PLoS One
1 Radiol Artif Intell
1 Radiology
2 Radiother Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Clin Oncol

  1. CRUTTENDEN J, Grant J, Evans J, Cannon G, et al
    Impact of Consensus Guidelines, Clinical Trials, and COVID-19 on Fractionation Practices for Node-negative Intact Breast Cancer.
    Am J Clin Oncol. 2025 Feb 4. doi: 10.1097/COC.0000000000001167.
    PubMed         Abstract available


    Ann Oncol

  2. GARCIA-MURILLAS I, Abbott CW, Cutts RJ, Boyle SM, et al
    Whole genome sequencing powered ctDNA sequencing for breast cancer detection.
    Ann Oncol. 2025 Feb 4:S0923-7534(25)00053-5. doi: 10.1016/j.annonc.2025.
    PubMed         Abstract available


    Ann Surg Oncol

  3. YOUNG J, Asaoka M, Ghasemi F, Chida K, et al
    The American Joint Committee on Cancer (AJCC) Breast Cancer Staging, Eighth Edition, is more Reflective of Cancer Biology than the Seventh Edition.
    Ann Surg Oncol. 2025 Feb 7. doi: 10.1245/s10434-025-16889.
    PubMed         Abstract available

  4. ZHANG M, Yuan L, Cui M, Chen J, et al
    ASO Author Reflections: Personal Insights and Reflections on the Burden of Breast Cancer Among Adolescents and Young Adults.
    Ann Surg Oncol. 2025 Feb 6. doi: 10.1245/s10434-024-16858.
    PubMed        

  5. LAWS A, Leonard S, Vincuilla J, Parker T, et al
    ASO Visual Abstract: Risk of Surgical Overtreatment in cN1 Breast Cancer Patients Who Become ypN0 After Neoadjuvant Chemotherapy: SLNB Versus TAD.
    Ann Surg Oncol. 2025 Feb 3. doi: 10.1245/s10434-025-16952.
    PubMed        

  6. COLEMAN-BELIN JC, Rubin J, Boe LA, Diwan R, et al
    Protective Factors Associated with Normal Lymphatic Function After Axillary Lymph Node Dissection for Breast Cancer Treatment.
    Ann Surg Oncol. 2025 Feb 3. doi: 10.1245/s10434-025-16918.
    PubMed         Abstract available


    Anticancer Res

  7. GOERDT L, Stefanovic A, Wirtz R, Karic U, et al
    Correlation of HLA-A and HLA-B/C Expression With ESR1 Expression in Patients With Metastatic Breast Cancer as a Potential Prognosticator of Favorable Distant Disease-free Survival.
    Anticancer Res. 2025;45:445-450.
    PubMed         Abstract available

  8. OSHIRO A, Nagahashi M, Togashi Y, Kanaoka H, et al
    Clinical Utility of Sentinel Lymph Node Biopsy Using the Medical Imaging Projection System in Breast Cancer Patients, Including Those Following Neoadjuvant Chemotherapy.
    Anticancer Res. 2025;45:789-796.
    PubMed         Abstract available

  9. YEARBY LA, Kotina M, Ohemeng A, Banjara B, et al
    Noncancerous Exosomes Establish a Growth Promoting Paracrine Effect on Triple Negative Breast Cancer Cells.
    Anticancer Res. 2025;45:419-431.
    PubMed         Abstract available

  10. MORINAGA S, Han Q, Mizuta K, Kang BM, et al
    Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose Ivermectin.
    Anticancer Res. 2025;45:451-455.
    PubMed         Abstract available

  11. SHIN D, Yoo JO, Jeong JH, Han YH, et al
    MiR-5586-5p Suppresses Hypoxia-induced Angiogenesis Through Multiple Targeting of HIF-1alpha, HBEGF and ADAM17 in Breast Cancer.
    Anticancer Res. 2025;45:473-489.
    PubMed         Abstract available


    BMC Cancer

  12. JIAO D, Chen X, Sun X, Lu Z, et al
    A comparative study of mitoxantrone hydrochloride injection and technetium-99 m for tracing axillary sentinel nodes in patients with breast cancer.
    BMC Cancer. 2025;25:209.
    PubMed         Abstract available

  13. YAMADA M, Chishima T, Ishikawa T, Narui K, et al
    Breast cancer risk assessment based on a predictive model: evaluation of risk factors among Japanese women.
    BMC Cancer. 2025;25:206.
    PubMed         Abstract available

  14. SHEIKHNEZHAD L, Hassankhani H, Sawin EM, Sanaat Z, et al
    What does intimate partner violence mean for women with breast cancer? Experiences of Iranian women.
    BMC Cancer. 2025;25:190.
    PubMed         Abstract available


    Br J Cancer

  15. ELLIOTT H, Allen AJ, Forester ND, Graziadio S, et al
    Women's perspectives of molecular breast imaging: a qualitative study.
    Br J Cancer. 2025;132:276-282.
    PubMed         Abstract available


    Breast Cancer

  16. PARK MS, Cho EH, Youn Y, Do IG, et al
    Importance of circulating tumor DNA analysis at diagnosis in early triple-negative breast cancer patients.
    Breast Cancer. 2025 Jan 31. doi: 10.1007/s12282-025-01673.
    PubMed         Abstract available

  17. TOKUNAGA E, Koi Y, Tajiri W, Koga C, et al
    The impact of breast surgery and systemic therapy on the survival of patients with de novo stage IV breast cancer.
    Breast Cancer. 2025 Feb 2. doi: 10.1007/s12282-025-01675.
    PubMed         Abstract available

  18. NAGAHASHI M, Kumamaru H, Kinukawa N, Iwamoto T, et al
    Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry-clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression.
    Breast Cancer. 2025 Feb 6. doi: 10.1007/s12282-025-01671.
    PubMed         Abstract available


    Breast Cancer (Dove Med Press)

  19. DONG X, Meng J, Xing J, Jia S, et al
    Predicting Axillary Lymph Node Metastasis in Young Onset Breast Cancer: A Clinical-Radiomics Nomogram Based on DCE-MRI.
    Breast Cancer (Dove Med Press). 2025;17:103-113.
    PubMed         Abstract available


    Breast Cancer Res

  20. LOPEZ M, Spehner L, Andre F, Viot J, et al
    Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption.
    Breast Cancer Res. 2025;27:19.
    PubMed         Abstract available

  21. WHITMARSH T, Cope W, Carmona-Bozo J, Manavaki R, et al
    Quantifying the tumour vasculature environment from CD-31 immunohistochemistry images of breast cancer using deep learning based semantic segmentation.
    Breast Cancer Res. 2025;27:17.
    PubMed         Abstract available

  22. GETZ KR, Jeon MS, Liu L, Liu L, et al
    Metabolites and lipid species mediate the associations of adiposity in childhood and early adulthood with mammographic breast density in premenopausal women.
    Breast Cancer Res. 2025;27:18.
    PubMed         Abstract available

  23. HENRICKS J, Haddad T, Ahmed O, Schoenhals J, et al
    Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer.
    Breast Cancer Res. 2025;27:16.
    PubMed         Abstract available


    Breast Cancer Res Treat

  24. MAYER EL, Smith ML, Guerin A, Latremouille-Viau D, et al
    Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2- early breast cancer: a discrete choice survey study.
    Breast Cancer Res Treat. 2025 Feb 7. doi: 10.1007/s10549-025-07627.
    PubMed         Abstract available

  25. SHIN E, Kim HM, Koo JS
    CD68 positive and/or CD163 positive tumor-associated macrophages and PD-L1 expression in breast phyllodes tumor.
    Breast Cancer Res Treat. 2025;209:261-273.
    PubMed         Abstract available

  26. ROSENBERGER LH, Thomas SM, Hieken TJ, Gallagher KK, et al
    Germline genetic mutations in a multi-center cohort of 248 phyllodes tumors.
    Breast Cancer Res Treat. 2025;209:275-282.
    PubMed         Abstract available

  27. SITU J, Walker C, Jayathungage Don TD, Suami H, et al
    Discordance between peritumoral and subareolar injections for mapping sentinel lymph nodes in the breast.
    Breast Cancer Res Treat. 2025;209:283-290.
    PubMed         Abstract available

  28. SAMAHA M, Fellner A, Raque K, Kuritzky A, et al
    Magnetic lymphatic tracing for omission of sentinel lymph node biopsies in mastectomy patients: a community cancer center experience.
    Breast Cancer Res Treat. 2025;209:161-166.
    PubMed         Abstract available

  29. CHIKARMANE SA, Gibson A, Chesebro AL, Giess CS, et al
    Frequency and outcomes of new or suspicious MRI findings on breast MRI for patients on neoadjuvant therapy.
    Breast Cancer Res Treat. 2025;209:521-531.
    PubMed         Abstract available

  30. JOGENDRAN M, Flemming JA, Djerboua M, Korzeniowski M, et al
    The association between cirrhosis and outcomes among female patients undergoing surgery for breast cancer in Ontario: a population-based study.
    Breast Cancer Res Treat. 2025 Feb 3. doi: 10.1007/s10549-025-07612.
    PubMed         Abstract available

  31. COOPER K, Nalbant G, Essat M, Harnan S, et al
    Gene expression profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review.
    Breast Cancer Res Treat. 2025 Feb 3. doi: 10.1007/s10549-024-07596.
    PubMed         Abstract available

  32. JANSEN BAM, Bargon CA, Bouman MA, van der Molen DRM, et al
    Patient-reported outcomes after immediate and delayed DIEP-flap breast reconstruction in the setting of post-mastectomy radiation therapy-results of the multicenter UMBRELLA breast cancer cohort.
    Breast Cancer Res Treat. 2025 Feb 3. doi: 10.1007/s10549-025-07613.
    PubMed         Abstract available

  33. BONADIO RC, Tavares MC, Balint FC, de Sousa IM, et al
    Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study.
    Breast Cancer Res Treat. 2025 Feb 3. doi: 10.1007/s10549-025-07628.
    PubMed         Abstract available

  34. PARK E, Peterson L, McKeon S, Fiala MA, et al
    Returning to work after breast cancer: a longitudinal analysis of employment and financial hardship.
    Breast Cancer Res Treat. 2025 Feb 2. doi: 10.1007/s10549-025-07624.
    PubMed         Abstract available

  35. HASHEMI MH, Moaiery H, Nikkhoo B, Zamani F, et al
    Molecular Dynamics of Breast Cancer Subtypes: The Role of FAM83H-AS1 Long Non-coding RNA in Breast Cancer Metastasis.
    Breast Cancer Res Treat. 2025 Feb 1. doi: 10.1007/s10549-024-07603.
    PubMed         Abstract available

  36. ERGAS IJ, Cheng RK, Roh JM, Kresovich JK, et al
    Diet quality and cardiometabolic health in breast cancer survivors: the Pathways Study.
    Breast Cancer Res Treat. 2025 Feb 1. doi: 10.1007/s10549-025-07629.
    PubMed         Abstract available

  37. AHMED GA, Baron DH, Agrawal A
    Oncologic and cosmetic outcomes of oncoplastic breast-conserving surgery after neoadjuvant systemic therapy: systematic review and meta-analysis.
    Breast Cancer Res Treat. 2025;209:229-252.
    PubMed         Abstract available

  38. NEUNER JM, Stolley M, Kamaraju S, Tiegs J, et al
    The association of distress and depression screening measures and other electronic health record information with adjuvant endocrine therapy persistence.
    Breast Cancer Res Treat. 2025;209:541-552.
    PubMed         Abstract available

  39. LONG R, Luo Y, Cao M, Cao K, et al
    Malignancy risk stratification prediction of BI-RADS 4B calcifications based on contrast-enhanced mammographic features: a multicenter study.
    Breast Cancer Res Treat. 2025;210:135-145.
    PubMed         Abstract available

  40. LI JJX, Ng JKM, Hon NKY, See KW, et al
    Effects on lymph node size, staging and primary tumor histology on diagnostic accuracy of axillary lymph node aspirate of breast cancers.
    Breast Cancer Res Treat. 2025;209:15-20.
    PubMed         Abstract available

  41. LEE CW, Shin HJ, Kim HJ, Baek S, et al
    Performance of high-resolution diffusion-weighted magnetic resonance imaging for detecting clinically occult early breast cancers: a multi-reader study.
    Breast Cancer Res Treat. 2025;210:71-86.
    PubMed         Abstract available

  42. SAKATANI T, Tsuda H, Yoshida M, Honma N, et al
    Current status and challenges in HER2 IHC assessment: scoring survey results in Japan.
    Breast Cancer Res Treat. 2025;210:27-36.
    PubMed         Abstract available

  43. KUO MC, Sims J, Solis OK, Meszoely IM, et al
    Disease recurrence in patients undergoing mastectomy for ductal carcinoma in situ.
    Breast Cancer Res Treat. 2025;209:675-679.
    PubMed         Abstract available


    Cancer

  44. MAZOR M, Lin JJ, Smith C, Rosa WE, et al
    Community-engaged adaptation of ACCESS: A navigator-led early palliative care intervention for Black and Latina women with advanced breast cancer.
    Cancer. 2025;131:e35745.
    PubMed         Abstract available


    Cancer Cell

  45. ZHANG Y, Chen H, Mo H, Zhao N, et al
    Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer.
    Cancer Cell. 2025 Jan 30:S1535-6108(25)00025-X. doi: 10.1016/j.ccell.2025.
    PubMed         Abstract available


    Cancer Epidemiol Biomarkers Prev

  46. SCHROTH W, Murdter TE, Schwab M
    Unraveling the Impact of Drug Metabolism on Tamoxifen Response in Breast Cancer.
    Cancer Epidemiol Biomarkers Prev. 2025;34:221-223.
    PubMed         Abstract available


    Cancer Lett

  47. YOU X, Hu X, Sun Z, Xu W, et al
    Dual targeting PPARalpha and NPC1L1 metabolic vulnerabilities blocks tumorigenesis.
    Cancer Lett. 2025;612:217493.
    PubMed         Abstract available

  48. GILON-ZALTSMAN O, Weidenfeld-Barenboim K, Samara H, Feuermann Y, et al
    Targeting dormant disseminated tumor cells and their permissive niche by pro-resolving mediators derived from resolution-phase macrophages.
    Cancer Lett. 2025;612:217468.
    PubMed         Abstract available


    Cancer Res

  49. METGE BJ, Williams L, Swain CA, Hinshaw DC, et al
    Ribosomal RNA Biosynthesis Functionally Programs Tumor-Associated Macrophages to Support Breast Cancer Progression.
    Cancer Res. 2025 Feb 4. doi: 10.1158/0008-5472.CAN-24-0707.
    PubMed         Abstract available

  50. MADORSKY ROWDO FP, Martini R, Ackermann SE, Tang CP, et al
    Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition.
    Cancer Res. 2025;85:551-566.
    PubMed         Abstract available

  51. TREMBATH HE, Spanheimer PM
    In Search of Representative Translational Cancer Model Systems.
    Cancer Res. 2025;85:407-409.
    PubMed         Abstract available


    Cell

  52. HU B, He R, Pang K, Wang G, et al
    High-resolution spatially resolved proteomics of complex tissues based on microfluidics and transfer learning.
    Cell. 2025;188:734-748.
    PubMed         Abstract available


    Clin Breast Cancer

  53. COUSINS L, Darragh L, Kerr B
    Health Information on Breast Cancer Surgery on YouTube(R).
    Clin Breast Cancer. 2025 Jan 15:S1526-8209(25)00013.
    PubMed         Abstract available

  54. KIM MJ, Kim HJ, Kim JY, Shin J, et al
    Effectiveness of Adjuvant Capecitabine in Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Treatment: A Real-World Evidence Study in Korea.
    Clin Breast Cancer. 2025 Jan 13:S1526-8209(24)00369.
    PubMed         Abstract available

  55. GODDING LTH, Dekker-Klaassen A, Volders JH, van Hezewijk M, et al
    The Added Value of Physical Examination for Breast Cancer Recurrence Detection in Women: A Systematic Review.
    Clin Breast Cancer. 2025 Jan 11:S1526-8209(24)00365.
    PubMed         Abstract available

  56. TRAPANI D, Jin Q, Miller KD, Rugo HS, et al
    Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials.
    Clin Breast Cancer. 2024 Dec 31:S1526-8209(24)00371.
    PubMed         Abstract available


    Clin Cancer Res

  57. GOEL S, Jovanovic B, Chu X, Hughes M, et al
    A phase II study of abemaciclib for patients with retinoblastoma-positive, triple-negative metastatic breast cancer.
    Clin Cancer Res. 2025 Feb 5. doi: 10.1158/1078-0432.CCR-24-2647.
    PubMed         Abstract available

  58. DRAKE RJG, Landen AH, Holmberg E, Stenmark Tullberg A, et al
    Endothelial cell pY397-FAK expression predicts risk of breast cancer recurrences after radiotherapy in SweBCG91-RT cohort.
    Clin Cancer Res. 2025 Feb 5. doi: 10.1158/1078-0432.CCR-24-2939.
    PubMed         Abstract available

  59. KOBOLD S
    RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different.
    Clin Cancer Res. 2025;31:437-438.
    PubMed         Abstract available

  60. JAEGER-RUCKSTUHL CA, Specht JM, Voutsinas JM, MacMillan HR, et al
    Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies.
    Clin Cancer Res. 2025;31:503-514.
    PubMed         Abstract available


    Eur Radiol

  61. MALHAIRE C, Umay O, Cockenpot V, Selhane F, et al
    Predicting axillary residual disease after neoadjuvant therapy in breast cancer using baseline MRI and ultrasound.
    Eur Radiol. 2025 Feb 8. doi: 10.1007/s00330-025-11408.
    PubMed         Abstract available

  62. ABDULLAH KA, Marziali S, Nanaa M, Escudero Sanchez L, et al
    Deep learning-based breast cancer diagnosis in breast MRI: systematic review and meta-analysis.
    Eur Radiol. 2025 Feb 5. doi: 10.1007/s00330-025-11406.
    PubMed         Abstract available

  63. D'ANGELO A, Caprini F, Adele Marino M
    Current status of breast cancer screening in transgender and gender-diverse populations.
    Eur Radiol. 2025 Jan 31. doi: 10.1007/s00330-025-11355.
    PubMed        


    Gene

  64. SAADH MJ, Bishoyi AK, Ballal S, Singh A, et al
    MicroRNAs as behind-the-scenes molecules in breast cancer metastasis and their therapeutic role through novel microRNA-based delivery strategies.
    Gene. 2025;944:149272.
    PubMed         Abstract available

  65. NOUH WE, El Azab EF, Oraby EA, Ahmed SM, et al
    Genetic variants and breast carcinoma susceptibility: Unveiling the role of MTHFR (rs1801131, rs1801133) and TP53 (rs1042522).
    Gene. 2025;942:149259.
    PubMed         Abstract available


    Histopathology

  66. RAKHA EA, Quinn C
    Controversies regarding encapsulated papillary carcinoma of the breast: an approach to evaluation and categorisation.
    Histopathology. 2025;86:497-513.
    PubMed         Abstract available

  67. CHAN R, Leung H, Li J, Poon I, et al
    Evaluation of breast-specific marker expression in metastatic breast cancers: Correlation with subtype switch.
    Histopathology. 2025;86:536-546.
    PubMed         Abstract available

  68. AI D, Arrey EN, Postlewait LM, Gao Y, et al
    The prevalence and clinical significance of residual occult breast cancer after neoadjuvant chemotherapy: reassessing surgical pathology in cases initially described as pathological complete response.
    Histopathology. 2025 Feb 4. doi: 10.1111/his.15417.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  69. SHAITELMAN SF
    ABLATIVE Radiation Therapy for Breast Cancer: The Time Has Come for Innovation.
    Int J Radiat Oncol Biol Phys. 2025;121:623-625.
    PubMed        

  70. VINASCO-SANDOVAL T, Moratille S, Crechet F, Mesloub Y, et al
    Long Noncoding VIM-AS1: Biomarker of Breast Fibrosis Susceptibility After Radiation Therapy and Promoter of Transforming Growth Factor Beta1-Driven Fibrosis.
    Int J Radiat Oncol Biol Phys. 2025;121:783-797.
    PubMed         Abstract available

  71. CIVIL YA, Vasmel JE, Charaghvandi RK, Houweling AC, et al
    Preoperative Magnetic Resonance Guided Single-Dose Partial Breast Irradiation: 5-Year Results of the Prospective Single-Arm ABLATIVE Trial.
    Int J Radiat Oncol Biol Phys. 2025;121:613-622.
    PubMed         Abstract available

  72. MA J, Shah R, Bell AC, McDermott N, et al
    Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors.
    Int J Radiat Oncol Biol Phys. 2025;121:768-779.
    PubMed         Abstract available


    J Clin Oncol

  73. ROBERTSON JFR, Shao Z, Noguchi S, Bondarenko I, et al
    Erratum: Fulvestrant Versus Anastrozole in Endocrine Therapy-Naive Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.
    J Clin Oncol. 2025 Feb 7:JCO2500116. doi: 10.1200/JCO-25-00116.
    PubMed        


    Lancet

  74. DUNN JA, Donnelly P, Elbeltagi N, Marshall A, et al
    Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial.
    Lancet. 2025;405:396-407.
    PubMed         Abstract available

  75. MANN RM
    Rethinking surveillance after breast cancer.
    Lancet. 2025;405:356-358.
    PubMed        


    Nature

  76. DOGLIONI G, Fernandez-Garcia J, Igelmann S, Altea-Manzano P, et al
    Aspartate signalling drives lung metastasis via alternative translation.
    Nature. 2025;638:244-250.
    PubMed         Abstract available


    NPJ Breast Cancer

  77. LADOIRE S, Kamga AM, Galland L, Reda M, et al
    Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib.
    NPJ Breast Cancer. 2025;11:10.
    PubMed         Abstract available

  78. MASTRANTONI L, Garufi G, Giordano G, Maliziola N, et al
    Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy.
    NPJ Breast Cancer. 2025;11:11.
    PubMed         Abstract available


    Oncogene

  79. GAO ZX, Li CL, Zhang H, Zhang GH, et al
    LINC00882, transcriptionally activated by CEBP-beta and post-transcriptionally stabilized by METTL14-mediated m(6)A modification, exerts tumorigenesis by promoting PABPC1-mediated stabilization of ELK3 mRNA.
    Oncogene. 2025;44:363-377.
    PubMed         Abstract available

  80. MAN KF, Darweesh O, Hong J, Thompson A, et al
    CREB1-BCL2 drives mitochondrial resilience in RAS GAP-dependent breast cancer chemoresistance.
    Oncogene. 2025 Jan 31. doi: 10.1038/s41388-025-03284.
    PubMed         Abstract available

  81. KONG Y, Lan T, Wang L, Gong C, et al
    Correction: BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression.
    Oncogene. 2025 Feb 3. doi: 10.1038/s41388-024-03250.
    PubMed        


    Oncology

  82. DING Y, Wu W, Ni X, Wang Z, et al
    Long-term survival of node-positive breast cancer with complete nodal response to neoadjuvant chemotherapy treated with sentinel lymph node biopsy alone: A meta-analysis.
    Oncology. 2025 Feb 3:1-23. doi: 10.1159/000543662.
    PubMed         Abstract available

  83. NISHIMURA R, Sudo K, Kitadai R, Kawachi A, et al
    Treatment and reasons for choosing treatment in breast cancer patients who underwent next-generation sequencing test.
    Oncology. 2025 Feb 4:1-21. doi: 10.1159/000543732.
    PubMed         Abstract available


    PLoS One

  84. LIU L, Meng Z, Yan J
    Efficacy of acupuncture in treating chemotherapy-related cognitive impairment in breast cancer patients: A systematic review and meta-analysis protocol.
    PLoS One. 2025;20:e0318984.
    PubMed         Abstract available

  85. LAI Y, Huang P
    Machine learning identifies the association between second primary malignancies and postoperative radiotherapy in young-onset breast cancer patients.
    PLoS One. 2025;20:e0316722.
    PubMed         Abstract available


    Radiol Artif Intell

  86. MARTINIUSSEN MA, Larsen M, Hovda T, Kristiansen MU, et al
    Performance of Two Deep Learning-based AI Models for Breast Cancer Detection and Localization on Screening Mammograms from BreastScreen Norway.
    Radiol Artif Intell. 2025 Feb 5:e240039. doi: 10.1148/ryai.240039.
    PubMed         Abstract available


    Radiology

  87. VAN WINKEL SL, Samperna R, Loehrer EA, Kroes J, et al
    Using AI to Select Women with Intermediate Breast Cancer Risk for Breast Screening with MRI.
    Radiology. 2025;314:e233067.
    PubMed         Abstract available


    Radiother Oncol

  88. CHUFAL KS, Ahmad I, Miller AA, Bajpai R, et al
    Machine learning model for predicting DIBH non-eligibility in left-sided breast cancer radiotherapy: Development, validation and clinical impact analysis.
    Radiother Oncol. 2025;205:110764.
    PubMed         Abstract available

  89. EOM A, Kirkwood D, Pond G, Hodgson N, et al
    Radiation therapy and immigration status in women with breast cancer.
    Radiother Oncol. 2025 Jan 31:110774. doi: 10.1016/j.radonc.2025.110774.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.